Back to today’s briefing

Story perspectives

BioNTech Founders Depart for New mRNA Venture Amid Leadership Shift

3/10/2026

34 3 Full Breakdown

Summary

Story summary

BioNTech co-founders Ugur Sahin and Özlem Türeci will leave by end of 2026 to start an mRNA venture.
BioNTech seeks a new CEO with late-stage development experience to become a multi-product company by 2030.
Analysts view the leadership change as logical, though investors worry about a 22% drop.
The new company will receive BioNTech’s mRNA technology for a minority stake and milestone payments.

History

Historical Context

The COVID-19 pandemic accelerated the development of mRNA vaccines, with BioNTech and Pfizer leading the charge. In December 2020, the UK became the first country to approve the Pfizer-BioNTech vaccine, which demonstrated over 90% efficacy. This breakthrough not only transformed vaccine technology but also positioned BioNTech for future growth as it aims to expand its mRNA applications beyond COVID-19 by 2030.

1 of 2

Story summary

BioNTech co-founders Ugur Sahin and Özlem Türeci will leave by end of 2026 to start an mRNA venture.
BioNTech seeks a new CEO with late-stage development experience to become a multi-product company by 2030.
Analysts view the leadership change as logical, though investors worry about a 22% drop.
The new company will receive BioNTech’s mRNA technology for a minority stake and milestone payments.

1 / 2